Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Japan Tissue Engineering Co's retained earnings for the quarter that ended in Mar. 2026 was 円-735 Mil.
Japan Tissue Engineering Co's quarterly retained earnings
declined
from Sep. 2025 (円-371 Mil) to Dec. 2025 (円-556 Mil) and
declined
from Dec. 2025 (円-556 Mil) to Mar. 2026 (円-735 Mil).
Japan Tissue Engineering Co's annual retained earnings
declined
from Mar. 2024 (円-1,667 Mil) to Mar. 2025 (円-1,922 Mil) but then
increased
from Mar. 2025 (円-1,922 Mil) to Mar. 2026 (円-735 Mil).
Japan Tissue Engineering Co (TSE:7774) Retained Earnings Explanation
Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.
For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.
If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.
Of course, many companies with negative retained earnings have indeed lost money in the past.
Retained Earnings: Warren Buffett's Secret.
One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.
If the company loses more than it has accumulated, retained earnings is negative.
If a company isn't adding to its retained earnings, it isn't growing its net worth.
Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.
Microsoft is negative because it chose to buyback stock and pay dividends.
The more earnings retained, the faster it grows and increases growth rate for future earnings.
Japan Tissue Engineering Co Retained Earnings Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Japan Tissue Engineering Co Retained Earnings Chart
Japan Tissue Engineering Co Retained Earnings Calculation
Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.
Of course, if a company loses, it is called retained losses, or accumulated losses.
Japan Tissue Engineering Co (TSE:7774) has a Retained Earnings of 円-735 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Japan Tissue Engineering Co and its competitors.
Is Japan Tissue Engineering Co's Retained Earnings too high?
Japan Tissue Engineering Co's current Retained Earnings is 円-735 Mil. Overall, Japan Tissue Engineering Co has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Retained Earnings compare to VRTX and REGN?
Japan Tissue Engineering Co's Retained Earnings of 円-735 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current Retained Earnings is 円-735 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円504.70, compared to a current price of 円820.00 — trading 62.5% above its estimated fair value. The current Retained Earnings is 円-735 Mil. Japan Tissue Engineering Co's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Retained Earnings is 円-735 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?
Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued.
The current stock price of 円820.00 is trading 62.5% above its estimated GF Value™ of 円504.70.
GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.
Key valuation signals for TSE:7774:
Retained Earnings: 円-735 Mil
GF Value™: 円504.70 vs. price of 円820.00 (62.5% above fair value)
No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
56GF Score
Get the complete analysis for TSE:7774
Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7774 has been successfully added to your 
